New combo aims to stall lung cancer when targeted pills start to fail
NCT ID NCT07669051
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether adding ivonescimab (an immunotherapy drug) to the current targeted therapy pill can help people with advanced non-small cell lung cancer whose disease is slowly progressing. The study involves 36 adults with a specific EGFR gene mutation. Researchers will measure how long the cancer stays under control and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ivonescimab (a drug that helps the immune system fight cancer) combined with an EGFR-TKI (a targeted cancer pill)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer whose disease is slowly getting worse on current targeted therapy.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shandong cancer hospital and institute
Jinan, Shandong, 250000, China